Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL11656570 | 0.94 | DAO (0.59) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL16334956 | 0.87 | DAO (0.50) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL12272115 | 0.84 | MAPT (0.57) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL22860217 | 0.82 | DAO (0.55) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL8779762 | 0.79 | DAO (0.52) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL27882567 | 0.79 | DAO (0.43) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL835069 | 0.79 | DAO (1.00) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL5104631 | 0.79 | PKM (0.52) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL22859920 | 0.77 | DAO (0.49) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL4968890 | 0.77 | HPGD (0.45) | KDM4EMAPTALDH1A1PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2236508-B1 | Reactive Heterocycle-Substituted 7-Hydroxycoumarins and Their Conjugates | BECTON DICKINSON CO (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8431416-B2 | Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates | BECTON, DICKINSON AND COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-8318953-B2 | Reactive coumarin derivatives and their use in cellular analyses | AAT BIOQUEST, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110318772-A1 | REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES | AAT BIOQUEST, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100255504-A1 | Reactive Heterocycle-Substituted 7-Hydroxycoumarins and Their Conjugates | BECTON, DICKINSON AND COMPANY (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2236508-A1 | Reactive Heterocycle-Substituted 7-Hydroxycoumarins and Their Conjugates | Becton, Dickinson and Company (US) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318772-A1 | REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES | CYP3A7, XPO7, HCCS | DAO 2806/4885KDM4E 4529/4885MAPT 3939/4885 |
| US-20100255504-A1 | Reactive Heterocycle-Substituted 7-Hydroxycoumarins and Their Conjugates | HLCS, CD44, HCCS | DAO 1355/4885KDM4E 2828/4885MAPT 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.